Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760146 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,902
- Enrollment target
NCT03760146 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,902 participants.
The verdict
NCT03760146, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,902 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
Interventions
- OTHER Saline
- BIOLOGICAL 13vPnC
- BIOLOGICAL PPSV23
- BIOLOGICAL 20vPnC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,902 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760146
The ClinicalTrials.gov registry entry for NCT03760146 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT03760146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03760146 about?
NCT03760146 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults". A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
What is the current status of trial NCT03760146?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,902 participants. The study started on 2018-12-12. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03760146?
The interventions under investigation include: Saline (OTHER), 13vPnC (BIOLOGICAL), PPSV23 (BIOLOGICAL), 20vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03760146?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.